CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)
Phase 3Recruiting 8 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory or Relapsed Multiple Myeloma
Conditions
Refractory or Relapsed Multiple Myeloma
Trial Timeline
Aug 12, 2025 → Jun 25, 2029
NCT ID
NCT06952478About CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) is a phase 3 stage product being developed by Celltrion for Refractory or Relapsed Multiple Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06952478. Target conditions include Refractory or Relapsed Multiple Myeloma.
What happened to similar drugs?
3 of 20 similar drugs in Refractory or Relapsed Multiple Myeloma were approved
Approved (3) Terminated (2) Active (15)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06952478 | Phase 3 | Recruiting |
Competing Products
20 competing products in Refractory or Relapsed Multiple Myeloma